Search company, investor...

Predict your next investment

Venture Capital
nlvpartners.com

Investments

214

Portfolio Exits

53

Funds

9

Service Providers

1

About New Leaf Venture Partners

New Leaf Venture Partners is a leader in healthcare technology venture investing. They focus primarily on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.

Headquarters Location

7 Times Square Suite 3502

New York, New York, 10036,

United States

646-871-6400

Want to inform investors similar to New Leaf Venture Partners about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Expert Collections containing New Leaf Venture Partners

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find New Leaf Venture Partners in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing New Leaf Venture Partners

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned New Leaf Venture Partners in 2 CB Insights research briefs, most recently on Feb 16, 2021.

Latest New Leaf Venture Partners News

Star Therapeutics Raises $90M in Series C Funding

Sep 5, 2023

Star Therapeutics , a South San Francisco, CA-based biotechnology company advancing antibody therapies, raised $90M in Series C funding. The round was led by Sofinnova Investments, and included new investors Qatar Investment Authority (QIA), Catalio Capital Management, Agent Capital, Soleus Capital, and NYBC Ventures, as well as participation from all existing investors including Westlake Village BioPartners, OrbiMed, Redmile Group, RA Capital Management, New Leaf Venture Partners, Cormorant Asset Management, and Cowen Healthcare Investments. Including this Series C round, Star Therapeutics has raised over $190m since inception to create numerous portfolio companies. The company intends to use the funds for clinical advancement of VGA039, a first-in-class antibody currently being evaluated in a Phase 1a/1b study for von Willebrand disease. This novel therapy is being developed by Vega Therapeutics, a Star portfolio company focused on underserved blood disorders. Proceeds will also be used to continue Star’s approach as an innovation engine to generate additional biotech companies focused on discovering and advancing novel antibody therapies, each targeting multiple diseases. Led by CEO Adam Rosenthal, Star Therapeutics is a biotechnology company that interrogates areas of novel biology to develop life-changing therapies for as many patients as possible, initially addressing needs in hematology and immunology. Its engine starts with identifying multiple diseases that share a common biology and then discovering novel therapeutics that can treat numerous diseases with a single therapy. Star consists of a constellation of companies, each focused on a specific area of biology with therapies. Concurrent with this financing, the Board will consist of Beth Seidenberg, MD, Founding Managing Director at Westlake Village BioPartners; Carl Gordon, PhD, Managing Partner at OrbiMed; Amrit Nagpal, Managing Director at Redmile Group, Maha Katabi, PhD, General Partner at Sofinnova Investments; Nancy Stagliano, PhD, Executive Board Chair; and Adam Rosenthal, PhD, CEO and Founder of Star. Star’s Board observers include Vijay Lathi, Founding Managing Director at New Leaf Venture Partners and Matt Hammond, PhD, Principal at RA Capital Management. FinSMEs 05/09/2023

New Leaf Venture Partners Investments

214 Investments

New Leaf Venture Partners has made 214 investments. Their latest investment was in Star Therapeutics as part of their Series C on September 9, 2023.

CBI Logo

New Leaf Venture Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/5/2023

Series C

Star Therapeutics

$90M

No

2

11/9/2022

Series B

CuraSen Therapeutics

$15M

No

1

7/26/2022

Series B

Arine

Yes

2

7/25/2022

Series C

Subscribe to see more

$99M

Subscribe to see more

10

3/14/2022

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/5/2023

11/9/2022

7/26/2022

7/25/2022

3/14/2022

Round

Series C

Series B

Series B

Series C

Series B - II

Company

Star Therapeutics

CuraSen Therapeutics

Arine

Subscribe to see more

Subscribe to see more

Amount

$90M

$15M

$99M

$99M

New?

No

No

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

1

2

10

10

New Leaf Venture Partners Portfolio Exits

53 Portfolio Exits

New Leaf Venture Partners has 53 portfolio exits. Their latest portfolio exit was Bellus Health on June 28, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/28/2023

Acq - P2P

$99M

6

1/20/2023

Acq - P2P

$99M

3

8/19/2022

Reverse Merger

$99M

4

4/7/2022

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

9/15/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/28/2023

1/20/2023

8/19/2022

4/7/2022

9/15/2021

Exit

Acq - P2P

Acq - P2P

Reverse Merger

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

6

3

4

10

10

New Leaf Venture Partners Fund History

9 Fund Histories

New Leaf Venture Partners has 9 funds, including New Leaf Ventures III.

Closing Date

Fund

Fund Type

Status

Amount

Sources

12/31/2015

New Leaf Ventures III

Multi-Stage Venture Capital

Closed

2

6/22/2015

New Leaf Growth Fund I

Subscribe to see more

Subscribe to see more

$99M

10

10/23/2007

New Leaf Ventures II

Subscribe to see more

Subscribe to see more

$99M

10

8/5/2005

New Leaf Ventures I LP

Subscribe to see more

Subscribe to see more

$99M

10

12/31/2000

Sprout Capital IX LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

12/31/2015

6/22/2015

10/23/2007

8/5/2005

12/31/2000

Fund

New Leaf Ventures III

New Leaf Growth Fund I

New Leaf Ventures II

New Leaf Ventures I LP

Sprout Capital IX LP

Fund Type

Multi-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Closed

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$99M

$99M

$99M

$99M

Sources

2

10

10

10

10

New Leaf Venture Partners Service Providers

1 Service Provider

New Leaf Venture Partners has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Counsel

Service Provider

Associated Rounds

Provider Type

Counsel

Service Type

Partnership data by VentureSource

New Leaf Venture Partners Team

13 Team Members

New Leaf Venture Partners has 13 team members, including , .

Name

Work History

Title

Status

Philippe Chambon

Founder

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Philippe Chambon

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Founder

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.